PATHFINDER 2

Pathfinder was a biotechnology company focused on the development of a novel class of specialized cells, known as Pathfinder cells, for the treatment of organ damage and degenerative diseases. These cells were characterized as a unique type of non-stem cell that could stimulate the regeneration of damaged tissues without the risks of tumor formation or immune rejection typically associated with stem cell therapies. The company's research primarily targeted high-unmet-need areas such as diabetes, renal failure, and cardiovascular conditions. Despite promising early-stage research and a proprietary platform, the company ceased active operations and its intellectual property was later involved in various licensing and asset discussions.